// App-Quantinova.ai

: Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

Researchers

Presenter

  • Natasha Mesinkovska

Principal Investigators

  • Jerry Shapiro

  • Brett King

  • Rodney Sinclair

  • Xingqi Zhang

  • Charles Lynde

  • Walter Gubelin Harcha

  • Jacek C Szepietowski

  • Dalia Wajsbrot

  • Liza Takiya

  • Robert Wolk

Medical Centers

  • School of Medicine, University of California, Irvine, Irvine, CA

  • New York University School of Medicine, New York, NY

  • Yale University School of Medicine, New Haven, CT

  • Sinclair Dermatology, Melbourne, Australia

  • Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • MSD, Santiago de Chile, Chile

  • Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland

Locations

  • United States

  • Chile

  • China

  • Poland

  • Canada

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Nuclear receptor subfamily 4 group A member 3

  • Janus kinase 3

Drug/Treatment

  • Frovatriptan succinate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT03732807

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved